•   
  •   

Health & Fitness J&J coronavirus vaccine can resume in US, CDC advisory panel recommends

06:05  24 april  2021
06:05  24 april  2021 Source:   livescience.com

Quick guide: COVID-19 vaccines in use and how they work

  Quick guide: COVID-19 vaccines in use and how they work Here's a guide to the vaccines being used in different countries.Dozens of coronavirus vaccines entered clinical trials during 2020, and now, a handful have been authorized for emergency use in various countries — meaning the shots can be administered to the public while their developers continue to collect data on their safety and efficacy. Should they meet all the necessary criteria, these vaccines could be fully approved in the future, and in some places, they already have been.

A CDC advisory panel voted to recommend that the U . S . resume administering the Johnson & Johnson vaccine for people 18 years of age and older. This comes after an 11-day pause in administering the vaccine prompted by reports of extremely rare, but severe, blood clots that developed post- vaccination in a handful of people. During an Advisory Committee on Immunization Practices meeting held on Friday (April 23), the panel voted 10 to 4 to resume Johnson & Johnson vaccination among all age groups, but they recommended that a warning label be added to include the possibility

A CDC advisory panel on Friday recommended the U . S . resume using the Johnson and Johnson Covid-19 vaccine . Members of the panel also proposed that the FDA include a warning label for women under age 50. The Food and Drug Administration and CDC on April 13 asked states to temporarily halt using J & J 's vaccine "out of an abundance of caution" following reports of the rare blood clots. Within hours of the warning, more than a dozen states as well as some national pharmacies halted inoculations with J & J 's vaccine , some replacing scheduled appointments with either the Pfizer

A Centers for Disease Control and Prevention (CDC) advisory panel voted to recommend that the U.S. resume administering the Johnson & Johnson vaccine for people 18 years of age and older. This comes after an 11-day pause in administering the vaccine prompted by reports of extremely rare, but severe, blood clots that developed post-vaccination in a handful of people.

A vaccine syringe in front of a Johnson and Johnson logo. © Provided by Live Science A vaccine syringe in front of a Johnson and Johnson logo.

During an Advisory Committee on Immunization Practices meeting held on Friday (April 23), the panel voted 10 to 4 to resume Johnson & Johnson vaccination among all age groups, but they recommended that a warning label be added to include the possibility that the vaccine may increase the risk of such blood clots.

THOUSANDS of Americans have had bad reactions to coronavirus vaccines

  THOUSANDS of Americans have had bad reactions to coronavirus vaccines Of more than 13.7 million coronavirus vaccine doses administered between mid-December 2020 and mid-January 2021, there were 6,994 reports of adverse events submitted to the CDC's reporting system.Nearly 7,000 people had an 'adverse event' after being given either the Pfizer-BioNTech or the Moderna shot, the Centers for Disease Control and Prevention (CDC) revealed on Friday.

(CNN) The US Centers for Disease Control and Prevention and Food and Drug Administration lifted their recommended pause on use of Johnson & Johnson's coronavirus vaccine Friday and said the label will be updated to warn of blood clot risks. Vaccinations could resume as soon as Saturday, the FDA said. The agencies acted quickly after a vote by the CDC 's Advisory Committee for Immunization Practices recommended lifting the pause. " We have concluded that the known and potential benefits of the Janssen COVID-19 vaccine outweigh its known and potential risks in individuals 18 years of age

CDC ’s independent advisory committee, the Advisory Committee on Immunization Practices, will continue to meet and discuss data on the evolution of the pandemic and the use of COVID-19 vaccines . According to information from the Vaccine Adverse Event Reporting System (VAERS), there were 653 reports of fainting events (fainting and near-fainting) among nearly 8 million doses of J & J /Janssen COVID-19 Vaccine administered in the United States in March and April 2021.

Now, the CDC will decide whether to accept the recommendation, according to NBC News.

Related: Quick guide: COVID-19 vaccines in use and how they work

The CDC and the Food and Drug Administration (FDA) had recommended a pause in Johnson & Johnson vaccinations in the U.S. on April 13 to investigate six cases of the rare clotting disorder recently coined as "thrombosis with thrombocytopenia syndrome" (TTS). In the week and a half since, officials have confirmed another nine cases, bringing the total to 15.

That's only a tiny proportion of the more than 8 million people who have been given the Johnson & Johnson vaccine in the U.S. so far, according to the CDC.  Of those cases, 13 were women between the ages of 18 and 49, and two were women who were 50 years of age or older. That means for women between the ages of 18 and 49, the risk of developing such blood clots appears to be 7 per million, and the risk for women who are 50 years of age or older appears to be 0.9 per million. There are another 10 cases that are currently under review, which may include males, according to the presenters at the ACIP.

Covid vaccine side effects: CDC warns of three new 'common side effects' to be aware of

  Covid vaccine side effects: CDC warns of three new 'common side effects' to be aware of ALL VACCINES come with the risk of side effects, but with the Covid vaccines being so new, the full extent of reactions is still being determined. The Centers for Disease Control and Prevention (CDC) has just updated its list of Covid vaccine side effects, adding three conditions that may occur following the jab.The CDC updated its vaccine guidance on March 5 and listed muscle pain among "common side effects".

An advisory panel with the US Centers for Disease Control and Prevention ( CDC ) voted on Sunday to approve the use of the Johnson & Johnson vaccine against the coronavirus for adults over 18. This is the third vaccine approved for use in the US . In December 2020, the regulator approved a vaccine developed in partnership between American company Pfizer and German company BioNTech, along with another vaccine produced by Moderna. On 26 February, US President Joe Biden announced that over 50 million American citizens had already been immunized.

An advisory panel for the Centers for Disease Control and Prevention voted in favor of resuming the Johnson & Johnson vaccination with a label warning about rare blood clots. 0:48 | 04/23/21. Now Playing: A CDC panel is meeting today to decide on the use of the Johnson & Johnson vaccine . Now Playing: Summer blockbusters return as movie theaters reopen. Now Playing: Harris delivers US Naval Academy commencement speech.

Three of those patients died and seven remain hospitalized. There wasn't a clear trend in risk factors among those who developed TTS other than being younger and female; seven were obese; two had hypothyroidism; two were using oral contraceptives; and two had high blood pressure.


Gallery: 10 ways COVID-19 changed the world (Live Science)

The group discussed a spectrum of options for how to proceed with Johnson & Johnson vaccinations in the U.S., including continuing the recommendation that the vaccine can be given to everyone 18 years of age and older and the option of setting an age limit since the cases of TTS appear more common in younger populations.

CDC scientist Dr. Sara Oliver presented risk/benefit modeling on these various scenarios. Their modeling suggests that continuing the Johnson & Johnson vaccine for everyone ages 18 and older may cause 26 to 45 cases of TTS but would prevent 600 to 1,400 deaths and 800 to 3,500 intensive care unit (ICU) admissions. It would also allow flexibility and ability to vaccinate harder-to-reach populations.

If they recommend the vaccine just for people 50 years of age or older, it would likely lead to two or three cases of TTS and prevent 300 to 1,000 ICU admissions and 40 to 250 deaths.

The experts did not see a good reason to stop using the Johnson & Johnson vaccine completely or limit its use to certain age groups. The discussion mainly centered around whether to recommend the Johnson & Johnson vaccine to everyone ages 18 and older or recommend it with a warning that women under the age of 50 "should be aware" of the increased risk of TTS and have an option of choosing another COVID-19 vaccine.

The Johnson & Johnson vaccine is an adenovirus-based vaccine that's similar to the one developed by AstraZeneca and the University of Oxford. The AstraZeneca vaccine has also prompted cases of TTS and was paused across many countries while being investigated; most countries have resumed administering the AstraZeneca shot but with various age restrictions and guidelines, Live Science previously reported.

Of the more than 214 million doses of mRNA vaccines — those made by Moderna and Pfizer — administered in the U.S., there have not been any reports of TTS.

On Tuesday (April 20), the European Medicines Agency concluded that there is a possible link between the J&J vaccine and rare cases of these blood clots and that a warning should be added to the product information; Johnson & Johnson announced the same day that it will resume shipment of its vaccine to the European Union, Norway and Iceland.

Originally published on Live Science.

CDC director pleads with US parents to vaccinate their teens .
A new CDC report published Friday found that 204 adolescents in 14 states were hospitalized primarily for COVID-19 with 31.4% admitted to ICUs and 4.9% requiring intubation,It comes as a new report from the federal health agency found that COVID-19-related hospitalizations in U.S. children between ages 12 and 17 rose by 116 percent in April.

usr: 1
This is interesting!